140 related articles for article (PubMed ID: 19016040)
21. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
22. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
23. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
24. Temporal resolution of urinary morbidity following prostate brachytherapy.
Merrick GS; Butler WM; Lief JH; Dorsey AT
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
[TBL] [Abstract][Full Text] [Related]
25. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
26. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
[TBL] [Abstract][Full Text] [Related]
27. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity.
Merrick GS; Butler WM; Wallner K; Galbreath RW; Anderson RL; Kurko BS; Lief JH
Urology; 2002 Jul; 60(1):104-8. PubMed ID: 12100933
[TBL] [Abstract][Full Text] [Related]
28. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
29. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
30. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
[TBL] [Abstract][Full Text] [Related]
31. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds.
Sugawara A; Nakashima J; Kunieda E; Nagata H; Asakura H; Oya M; Shigematsu N
Radiat Oncol; 2010 Sep; 5():86. PubMed ID: 20875137
[TBL] [Abstract][Full Text] [Related]
32. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
[TBL] [Abstract][Full Text] [Related]
33. Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose (125)I seeds.
Sugawara A; Nakashima J; Kunieda E; Nagata H; Mizuno R; Takeda A; Seki S; Shiraishi Y; Kouta R; Oya M; Shigematsu N
Keio J Med; 2012; 61(3):89-94. PubMed ID: 23018491
[TBL] [Abstract][Full Text] [Related]
34. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
[TBL] [Abstract][Full Text] [Related]
35. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
36. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
37. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
38. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.
Zelefsky MJ; Yamada Y; Marion C; Sim S; Cohen G; Ben-Porat L; Silvern D; Zaider M
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):956-63. PubMed ID: 12605973
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
40. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
